Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy

Apoptosis or programmed cell death is a key regulator of physiological growth control and regulation of tissue homeostasis. One of the most important advances in cancer research in recent years is the recognition that cell death mostly by apoptosis is crucially involved in the regulation of tumor formation and also critically determines treatment response. Killing of tumor cells by most anticancer strategies currently used in clinical oncology, for example, chemotherapy, γ-irradiation, suicide gene therapy or immunotherapy, has been linked to activation of apoptosis signal transduction pathways in cancer cells such as the intrinsic and/or extrinsic pathway. Thus, failure to undergo apoptosis may result in treatment resistance. Understanding the molecular events that regulate apoptosis in response to anticancer chemotherapy, and how cancer cells evade apoptotic death, provides novel opportunities for a more rational approach to develop molecular-targeted therapies for combating cancer.

[1]  J Downward,et al.  Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain , 2002, Cell Death and Differentiation.

[2]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[3]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Martin Schuler,et al.  Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.

[5]  Emad S. Alnemri,et al.  A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis , 2001, Nature.

[6]  G. Kroemer,et al.  The Central Executioner of Apoptosis: Multiple Connections between Protease Activation and Mitochondria in Fas/APO-1/CD95- and Ceramide-induced Apoptosis , 1997, The Journal of experimental medicine.

[7]  John Calvin Reed,et al.  Conversion of Bcl-2 from Protector to Killer by Interaction with Nuclear Orphan Receptor Nur77/TR3 , 2004, Cell.

[8]  H. Pehamberger,et al.  bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice , 1998, Nature Medicine.

[9]  D. Green,et al.  DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. , 1998, Molecular cell.

[10]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[11]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[12]  Petr Pancoska,et al.  p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.

[13]  A. Giaccia,et al.  Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. , 2002, Cancer cell.

[14]  Shaomeng Wang,et al.  Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. , 2005, Bioorganic & medicinal chemistry letters.

[15]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[16]  M. Peter,et al.  Activation of Mitochondria and Release of Mitochondrial Apoptogenic Factors by Betulinic Acid* , 1998, The Journal of Biological Chemistry.

[17]  S. B. Bratton,et al.  Recruitment, activation and retention of caspases‐9 and ‐3 by Apaf‐1 apoptosome and associated XIAP complexes , 2001, The EMBO journal.

[18]  B. Zhivotovsky,et al.  Caspase-2 Permeabilizes the Outer Mitochondrial Membrane and Disrupts the Binding of Cytochrome c to Anionic Phospholipids* , 2004, Journal of Biological Chemistry.

[19]  H. Koeppen,et al.  Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4 , 2001, The Journal of Immunology.

[20]  Alexei Degterev,et al.  A decade of caspases , 2003, Oncogene.

[21]  Tak W. Mak,et al.  Pathways of apoptotic and non-apoptotic death in tumour cells , 2004, Nature Reviews Cancer.

[22]  G. Kroemer,et al.  AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis , 2004, Oncogene.

[23]  R. Rich,et al.  Requirement of Both the Second and Third BIR Domains for the Relief of X-linked Inhibitor of Apoptosis Protein (XIAP)-mediated Caspase Inhibition by Smac* , 2003, Journal of Biological Chemistry.

[24]  S. Lowe,et al.  Suppression of tumorigenesis by the p53 target PUMA. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Srinivasula,et al.  Caspase-2 Induces Apoptosis by Releasing Proapoptotic Proteins from Mitochondria* , 2002, The Journal of Biological Chemistry.

[26]  W. Deppert,et al.  Transcription-independent pro-apoptotic functions of p53. , 2005, Current opinion in cell biology.

[27]  Clemencia Pinilla,et al.  Cellular, Biochemical, and Genetic Analysis of Mechanism of Small Molecule IAP Inhibitors* , 2004, Journal of Biological Chemistry.

[28]  Shaomeng Wang,et al.  Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. , 2004, Journal of medicinal chemistry.

[29]  A. Fornace,et al.  The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  A. Österborg,et al.  Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D , 2001, Leukemia.

[31]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[32]  Gerolama Condorelli,et al.  PED mediates AKT-dependent chemoresistance in human breast cancer cells. , 2005, Cancer research.

[33]  S. Fulda,et al.  Targeting apoptosis pathways in cancer therapy. , 2004, Current cancer drug targets.

[34]  E. White,et al.  Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. , 2005, Cancer cell.

[35]  M. Hengartner The biochemistry of apoptosis , 2000, Nature.

[36]  J. Skepper,et al.  Paclitaxel Affects Cytosolic Calcium Signals by Opening the Mitochondrial Permeability Transition Pore* , 2002, The Journal of Biological Chemistry.

[37]  G. Kroemer,et al.  Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death? , 2002, Journal of Cell Science.

[38]  P. Krammer,et al.  FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis , 2001, Molecular and Cellular Biology.

[39]  R. Stahel,et al.  Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. , 2001, Journal of the National Cancer Institute.

[40]  S. Lowe,et al.  Generation and Characterization of Smac/DIABLO-Deficient Mice , 2002, Molecular and Cellular Biology.

[41]  A. Ashkenazi,et al.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.

[42]  S. Fulda,et al.  Apoptosis in hematological disorders. , 2003, Seminars in cancer biology.

[43]  W. El-Deiry,et al.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.

[44]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.

[45]  M. Nau,et al.  Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines , 2000, Breast Cancer Research and Treatment.

[46]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[47]  Joanna K. Sax,et al.  BID regulation by p53 contributes to chemosensitivity , 2002, Nature Cell Biology.

[48]  M. Gleave,et al.  A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells , 2005, Molecular Cancer Therapeutics.

[49]  F. Oriente,et al.  Omi/HtrA2 Promotes Cell Death by Binding and Degrading the Anti-apoptotic Protein ped/pea-15* , 2004, Journal of Biological Chemistry.

[50]  H. Pehamberger,et al.  Chemosensitisation of malignant melanoma by BCL2 antisense therapy , 2000, The Lancet.

[51]  S. Fulda,et al.  Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells , 1997, Leukemia.

[52]  K. Debatin,et al.  Mutation analysis of the apoptotic “death‐receptors” and the adaptors TRADD and FADD/MORT‐1 in osteosarcoma tumor samples and osteosarcoma cell lines , 2004, International journal of cancer.

[53]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[54]  Y. Tsujimoto,et al.  Involvement of Histone H1.2 in Apoptosis Induced by DNA Double-Strand Breaks , 2003, Cell.

[55]  T L Chenevert,et al.  Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Krammer,et al.  CD95's deadly mission in the immune system , 2000, Nature.

[57]  B. Zhivotovsky,et al.  Distinct Pathways for Stimulation of Cytochrome cRelease by Etoposide* , 2000, The Journal of Biological Chemistry.

[58]  Ximena Opitz-Araya,et al.  Requirement for Caspase-2 in Stress-Induced Apoptosis Before Mitochondrial Permeabilization , 2002, Science.

[59]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[60]  P. Vandenabeele,et al.  Toxic proteins released from mitochondria in cell death , 2004, Oncogene.

[61]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[62]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[63]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[64]  W. May,et al.  Phosphorylation of Bcl2 and regulation of apoptosis , 2001, Leukemia.

[65]  K. Kinzler,et al.  PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.

[66]  H. Nakayama,et al.  A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. , 2001, Molecular cell.

[67]  Dajun Yang,et al.  Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. , 2004 .

[68]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.

[69]  Y. Hamada,et al.  Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95‐mediated apoptosis by down‐regulating FLIP‐L expression , 2000, International journal of cancer.

[70]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[71]  Z. Wang,et al.  Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.

[72]  D. Green,et al.  The Pathophysiology of Mitochondrial Cell Death , 2004, Science.

[73]  P. Galle,et al.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.

[74]  D. Trisciuoglio,et al.  Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2Gene–Amplified Breast Cancer Cells , 2004, Clinical Cancer Research.

[75]  H. Tagawa,et al.  Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.

[76]  S. Fulda,et al.  Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression , 2002, Oncogene.

[77]  D. Vaux,et al.  Mammalian mitochondrial IAP binding proteins. , 2003, Biochemical and biophysical research communications.

[78]  Shaomeng Wang,et al.  Structure-based design of potent, conformationally constrained Smac mimetics. , 2004, Journal of the American Chemical Society.

[79]  W L Allen,et al.  c-FLIP inhibits chemotherapy-induced colorectal cancer cell death , 2006, Oncogene.

[80]  Mark H Ellisman,et al.  Disruption of Mitochondrial Function during Apoptosis Is Mediated by Caspase Cleavage of the p75 Subunit of Complex I of the Electron Transport Chain , 2004, Cell.

[81]  I. Bechmann,et al.  Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) , 2000, The Lancet.

[82]  D. Goeddel,et al.  FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. , 1998, Science.

[83]  I. Weissman,et al.  Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. , 1998, Immunity.

[84]  W. el-Deiry,et al.  Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling , 2001, Cell Death and Differentiation.

[85]  D. Botstein,et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.

[86]  W. El-Deiry,et al.  p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. , 2001, Experimental cell research.

[87]  E. Solary,et al.  Cisplatin-Induced CD95 Redistribution into Membrane Lipid Rafts of HT29 Human Colon Cancer Cells , 2004, Cancer Research.

[88]  Sten Orrenius,et al.  Caspase-2 Acts Upstream of Mitochondria to Promote Cytochromec Release during Etoposide-induced Apoptosis* , 2002, The Journal of Biological Chemistry.

[89]  E. Solary,et al.  STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. , 1999, Biochemical and biophysical research communications.

[90]  Geng Wu,et al.  Structural basis of IAP recognition by Smac/DIABLO , 2000, Nature.

[91]  G. Kroemer,et al.  Chemotherapy: targeting the mitochondrial cell death pathway , 2002, Oncogene.

[92]  Xiaodong Wang,et al.  Structural and biochemical basis of apoptotic activation by Smac/DIABLO , 2000, Nature.

[93]  Jean-Claude Martinou,et al.  Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli , 2002, The Journal of cell biology.

[94]  S. Fulda,et al.  Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system , 1998, International journal of cancer.

[95]  B. Zhivotovsky,et al.  Processed caspase‐2 can induce mitochondria‐mediated apoptosis independently of its enzymatic activity , 2004, EMBO Reports.

[96]  M. Weller,et al.  CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release , 2001, Oncogene.

[97]  J. Tschopp,et al.  The PIDDosome, a Protein Complex Implicated in Activation of Caspase-2 in Response to Genotoxic Stress , 2004, Science.

[98]  G. Kroemer,et al.  Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis , 2001, Oncogene.

[99]  B. Zhivotovsky,et al.  Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide. , 2004, Experimental cell research.

[100]  T. Mak,et al.  Specific Ablation of the Apoptotic Functions of Cytochrome c Reveals a Differential Requirement for Cytochrome c and Apaf-1 in Apoptosis , 2005, Cell.

[101]  S. Srinivasula,et al.  The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity , 2002, Cell Death and Differentiation.

[102]  M. Peter,et al.  Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor. , 1995, The EMBO journal.

[103]  G. Wilson,et al.  Apoptosis Genes and Resistance to Cancer Therapy: What Does the Experimental and Clinical Data Tell Us? , 2003, Cancer biology & therapy.

[104]  Martin Schuler,et al.  Cytochrome C Maintains Mitochondrial Transmembrane Potential and Atp Generation after Outer Mitochondrial Membrane Permeabilization during the Apoptotic Process , 2001, The Journal of cell biology.

[105]  J. Downward,et al.  The Serine Protease Omi/HtrA2 Regulates Apoptosis by Binding XIAP through a Reaper-like Motif* , 2002, The Journal of Biological Chemistry.

[106]  A. Strasser The role of BH3-only proteins in the immune system , 2005, Nature Reviews Immunology.

[107]  Michael Weller,et al.  Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.

[108]  Seamus J. Martin,et al.  Regulation of Apoptotic Protease Activating Factor-1 Oligomerization and Apoptosis by the WD-40 Repeat Region* , 1999, The Journal of Biological Chemistry.

[109]  T. Hashikawa,et al.  Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways , 2004, Cell Death and Differentiation.

[110]  Jian Zhao,et al.  Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo , 2006, Cancer Gene Therapy.

[111]  W. El-Deiry,et al.  Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[112]  Rachel L. Allen,et al.  Defying death after DNA damage , 2000, Nature.

[113]  F. Cotter Unraveling biologic therapy for Bcl-2-expressing malignancies. , 2004, Seminars in oncology.

[114]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[115]  Clemencia Pinilla,et al.  Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. , 2004, Cancer cell.

[116]  L. Attardi,et al.  The role of apoptosis in cancer development and treatment response , 2005, Nature Reviews Cancer.

[117]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[118]  José Luis de la Pompa,et al.  Differential Requirement for Caspase 9 in Apoptotic Pathways In Vivo , 1998, Cell.

[119]  P. Bouillet,et al.  Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[120]  L. Berczi,et al.  Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma , 2003, Cell Death and Differentiation.

[121]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[122]  C. Belka,et al.  Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL , 2001, Oncogene.

[123]  Xiaodong Wang,et al.  A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death , 2004, Science.

[124]  F. Talos,et al.  Mitochondrially targeted p53 has tumor suppressor activities in vivo. , 2005, Cancer research.

[125]  Gail Walker,et al.  Apaf-1 Oligomerizes into Biologically Active ∼700-kDa and Inactive ∼1.4-MDa Apoptosome Complexes* , 2000, The Journal of Biological Chemistry.

[126]  J. Beckmann,et al.  Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. , 1998, Immunity.

[127]  J C Reed,et al.  Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.

[128]  T. Mak,et al.  Apaf1 Is Required for Mitochondrial Pathways of Apoptosis and Brain Development , 1998, Cell.

[129]  G. Gores,et al.  Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ * , 2002, The Journal of Biological Chemistry.

[130]  F. Alt,et al.  Proapoptotic BID is required for myeloid homeostasis and tumor suppression. , 2003, Genes & development.

[131]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[132]  J. Norris,et al.  Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[133]  I. McNeish,et al.  Expression of Smac/DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9-mediated pathway. , 2003, Experimental cell research.

[134]  W. El-Deiry,et al.  Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[135]  P. Krammer,et al.  The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.

[136]  Xiaodong Wang,et al.  Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.

[137]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[138]  G. Kroemer,et al.  Mitochondrion as a novel target of anticancer chemotherapy. , 2000, Journal of the National Cancer Institute.

[139]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[140]  H. Friess,et al.  The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract , 1999, Oncogene.

[141]  John Calvin Reed,et al.  Dysregulation of apoptosis genes in hematopoietic malignancies , 2002, Oncogene.

[142]  Emad S. Alnemri,et al.  Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi , 2002, Nature Structural Biology.

[143]  R. Coombes,et al.  FoxO3a Transcriptional Regulation of Bim Controls Apoptosis in Paclitaxel-treated Breast Cancer Cell Lines* , 2003, Journal of Biological Chemistry.

[144]  A. Strasser,et al.  BH3-only proteins - evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death. , 2002, Journal of cell science.

[145]  T. Sumi,et al.  Molecular-dynamics study of liquid mercury in the density region between metal and nonmetal , 1999 .

[146]  S. Nagata Apoptotic DNA fragmentation. , 2000, Experimental cell research.

[147]  J. Houghton,et al.  Thymineless death in colon carcinoma cells is mediated via fas signaling. , 1997, Proceedings of the National Academy of Sciences of the United States of America.